INOVIO Pharmaceuticals
NEWS ALERT

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Press Releases

INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants

Posted on November 30, 2021

INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201

Posted on November 16, 2021

INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference

Posted on November 15, 2021

INOVIO Reports Third Quarter 2021 Financial Results

Posted on November 9, 2021

INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.

Posted on November 9, 2021

INOVIO Expands Executive Leadership to Prepare for Commercial Operations

Posted on November 5, 2021

INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India

Posted on November 3, 2021

INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021

Posted on October 27, 2021

INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa

Posted on October 26, 2021

INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives

Posted on October 21, 2021

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.